USFDA And MHRA Approvals Will Unlock New Global Markets

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

02 Feb 25

Updated

24 Jul 25

Views

15

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-12.1%

7D

-4.0%

Loading

1Y

-12.1%

7D

-4.0%

You can edit this narrative until Jul 24 4:35 AM. Then, changes will post as Updates.

Author's Valuation

₹62839.5% undervalued

AnalystConsensusTarget Fair Value

Shared on 24 Jul 25

As both the Net Profit Margin and Revenue Growth forecasts for Aarti Drugs remain unchanged, consensus analyst expectations for the company's fair value are also steady, with the price target holding at ₹628.00. What's in the News Board meeting scheduled to consider and approve audited financial results for the quarter ended June 30, 2025.

Shared on 01 May 25

Fair value Increased 32%

Shared on 23 Apr 25

Fair value Increased 2.87%

AnalystConsensusTarget has decreased shares outstanding growth rate from -0.0% to -0.0%.

Shared on 17 Apr 25

Fair value Decreased 2.79%

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 2.31%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 12 Mar 25

Fair value Decreased 2.18%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget Fair Value

₹628

39.5% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

13.72%

Pharma revenue growth rate

0.68%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

12.76%

Calculation

₹3.86b

Earnings '28

x

21.22x

PE Ratio '28

=

₹81.86b

Market Cap '28

₹81.86b

Market Cap '28

/

91.27m

No. shares '28

=

₹896.95

Share Price '28

₹896.95 Share Price '28

Discounted to 2025 @ 12.73% p.a.

=

₹626.14

Fair Value '25